Results 181 to 190 of about 1,370,182 (310)

ANK1 and EPB41 Variants and The Risk of Glucocorticoid‐Induced Osteonecrosis

Arthritis &Rheumatology, EarlyView.
Objective Steroid‐induced osteonecrosis of the femoral head (SONFH) is a refractory skeletal disorder influenced by genetic and environmental factors. However, conclusive pathogenic genetic evidence remains elusive due to the limited exploration of rare damaging variants. In this study, we aimed to identify rare variants associated with SONFH.
Shengbao Chen, Xianmin Zhu, Zhongzhong Chen, Wei Chen, Hussam Alkaissi, Zeng Zhang, Yun Gao, Junhui Yin, Xiangtian Yu, Qiong Fu, Youshui Gao, Zhenzhong Zhu, Qianying Cai, Pengwei Zhang, Weibin Chen, Xin Zhao, Xiaojin Wu, Karel Pacak, Dongxu Jin, Chunde Bao, Zhengping Zhuang, Changqing Zhang   +21 more
wiley   +1 more source

Bridging the Gap Between Regulatory Approval and Patient Access: The Case for Insurance Coverage of Approved Allogeneic Stem Cell Therapy in Knee Osteoarthritis. [PDF]

Cureus
Agarwal AK, Das G, Aggarwal P, Danda R.
europepmc   +1 more source

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems

Arthritis &Rheumatology, EarlyView.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHRs) data has limited the ability to generate real‐world evidence (RWE).
David Cheng, Xuan Wang, Gregory C. McDermott, Jennifer S. Hanberg, Zoe Love, Katherine Zhong, Mary Jeffway, Jue Hou, Vidul Panickan, Rahul Sangar, Ying Qi, Connor Melley, Lauren Costa, Dakota Feil, Rachael Matty, Dana Weisenfeld, Abisayo Animashaun, Aimee Schreiner, Sara Morini, Lauren Rusnak, Andrew Cagan, Misti Paudel, J. Michael Gaziano, Brian Sauer, Michael Weinblatt, Joshua Baker, Bryant England, Yuk‐Lam Ho, Kelly Cho, Paul Monach, Grant W. Cannon, Nancy Shadick, Ted R. Mikuls, Tianxi Cai, Katherine P. Liao   +34 more
wiley   +1 more source

Association of Medicaid expansion with children's insurance coverage and healthcare utilization. [PDF]

Health Aff Sch
Dalziel K, Chua KP, Hua X, Huang L, Ryan A, Freed GL, Levy H, Ayanian JZ.   +7 more
europepmc   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Strategic Delay and Bargaining Over Public Insurance Coverage for Drugs in Australia. [PDF]

Health Econ
Li JJ, Harris A.
europepmc   +1 more source

Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao, Sasha Bernatsky, Sharon Dowell, Brittany Banbury, Jeffrey R. Curtis, Grace C. Wright, Emily E. Holladay, Amy Mudano, Cristiano S. Moura, Gail S. Kerr   +9 more
wiley   +1 more source

Population-Level Trends in Gastric Cancer Mortality and Incidence After Expansion of Japanese National Health Insurance Coverage for Helicobacter pylori Eradication: A Descriptive Time-Trend Study. [PDF]

Helicobacter
Asaka M, Tanuma T, Kowada A, Matsushima S, Akino K.   +4 more
europepmc   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Optimal insurance coverage and pricing of outpatient drugs in Iran: a cost- and chronicity-based adaptation of the vertical equity model. [PDF]

Int J Equity Health
Momahhed SS, Haghighathoseini A.
europepmc   +1 more source